RAS Extended Profiling Analysis by NGS

RAS extended profiling analysis by Next-Generation Sequencing (NGS) plays a pivotal role in understanding colorectal cancer (CRC). RAS mutations, including KRAS, NRAS, and HRAS, are known culprits in CRC, with KRAS mutations alone accounting for 40% of cases.

The Extended RAS profiling panel targets somatic mutations in KRAS, NRAS, and BRAF genes, providing critical information for tumor development, prognostic assessment, and predicting responses to chemotherapy and targeted therapies. 

Reportable mutations are meticulously prioritized in accordance with AMP-ASCO-CAP guidelines. In the case of RAS-mutant metastatic CRC, treatment strategies often involve combinations of chemotherapy drugs like 5-fluorouracil, oxaliplatin, and irinotecan, alongside antiangiogenic agents such as bevacizumab and aflibercept. This cutting-edge analysis empowers clinicians to make informed decisions, tailoring treatments to match the unique genetic makeup of each patient's tumor, ultimately improving outcomes and enhancing the quality of cancer care.

Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.